CFH: A Drug Target / Disease Biomarker (G3075)

Target Name: CFH

NCBI ID: G3075

Content of Review Report on CFH Target / Biomarker

CFH

CFH: A Drug Target / Disease Biomarker

CFH, short for Complement Factor H, is a protein that is expressed in most tissues of the body. It is a member of the complement system, which is a group of proteins that work together to help the body fight off infections. CFH is a key player in this system, as it helps to activate the complement system and stimulate the production of antibodies.

One of the things that makes CFH so important is its ability to recognize and bind to certain molecules in the body, such as bacteria and viruses. When a pathogen enters the body, CFH is the first protein to recognize it and begin to stimulate the production of antibodies. These antibodies work together with other immune cells, such as T cells and B cells, to help the body fight off the infection.

CFH is also involved in the regulation of the immune response. It helps to keep the immune system in check, so that it doesn't become too active and cause unnecessary reactions. This is important because when the immune system becomes too active, it can cause damage to the body's tissues and organs.

CFH is also a potential drug target. Researchers are interested in using it as a target for new treatments because it is involved in so many important processes in the body. For example, some researchers are studying the potential uses of CFH as a treatment for cancer, because it has been shown to have anti-tumor effects in animal studies.

CFH is also a potential biomarker. Researchers are interested in using it as a tool to diagnose and monitor certain diseases. For example, some researchers are studying the potential uses of CFH as a diagnostic tool for multiple sclerosis, a progressive neurodegenerative disease that affects the central nervous system.

In addition to its potential uses as a drug target and biomarker, CFH is also an important protein that helps keep the immune system healthy. It is a key player in the regulation of the immune response, and its absence or dysfunction can have serious consequences for the body.

CFH is a protein that is expressed in most tissues of the body. It is a member of the complement system, which is a group of proteins that work together to help the body fight off infections. CFH is a key player in this system, as it helps to activate the complement system and stimulate the production of antibodies. It is also involved in the regulation of the immune response and has the potential to be a drug target or biomarker.

Protein Name: Complement Factor H

Functions: Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Acts as a soluble inhibitor of complement, where its binding to self markers such as glycan structures prevents complement activation and amplification on cell surfaces (PubMed:21285368, PubMed:25402769). Accelerates the decay of the complement alternative pathway (AP) C3 convertase C3bBb, thus preventing local formation of more C3b, the central player of the complement amplification loop (PubMed:19503104, PubMed:26700768). As a cofactor of the serine protease factor I, CFH also regulates proteolytic degradation of already-deposited C3b (PubMed:23332154, PubMed:18252712, PubMed:28671664). In addition, mediates several cellular responses through interaction with specific receptors. For example, interacts with CR3/ITGAM receptor and thereby mediates the adhesion of human neutrophils to different pathogens. In turn, these pathogens are phagocytosed and destroyed (PubMed:9558116, PubMed:20008295)

The "CFH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets